Evidence map›Paper›PMID 39299564›Full record

ArticleVirologica Sinica2024

A novel vesicular stomatitis virus armed with IL-2 mimic for oncolytic therapy.

Manman Wu, Yiwei Wang, Chuanjian Wu, Huang Huang, Xinyuan Zhou, Jun Wang, Sidong Xiong, Chunsheng Dong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virologica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Manman WuThe Institutes of Biology and Medical Sciences, MOE Key Laboratory of Geriatric Diseases and Immunology, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou 215123, China.
Yiwei WangThe Institutes of Biology and Medical Sciences, MOE Key Laboratory of Geriatric Diseases and Immunology, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou 215123, China.
Chuanjian WuThe Institutes of Biology and Medical Sciences, MOE Key Laboratory of Geriatric Diseases and Immunology, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou 215123, China.
Huang HuangDepartment of Cardiology, No. 981 Hospital, PLA (People's Liberation Army of China), Chengde 067000, China.
Xinyuan ZhouInstitute of Immunology, College of Basic Medical Sciences, Third Military Medical University, Chongqing 400038, China. Electronic address: xinyuanzhou@tmmu.edu.cn.
Jun WangThe Institutes of Biology and Medical Sciences, MOE Key Laboratory of Geriatric Diseases and Immunology, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou 215123, China. Electronic address: jwang79@suda.edu.cn.
Sidong XiongThe Institutes of Biology and Medical Sciences, MOE Key Laboratory of Geriatric Diseases and Immunology, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou 215123, China. Electronic address: sdxiong@suda.edu.cn.
Chunsheng DongThe Institutes of Biology and Medical Sciences, MOE Key Laboratory of Geriatric Diseases and Immunology, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou 215123, China. Electronic address: chunshengdong@suda.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic virus (OV) is increasingly being recognized as a novel vector in cancer immunotherapy. Increasing evidence suggests that OV has the ability to change the immune status of tumor microenvironment, so called transformation of 'cold' tumors into 'hot' tumors. The improved anti-tumor immunity can be induced by OV and further enhanced through the combination of various immunomodulators. The Neo-2/15 is a newly de novo synthesized cytokine that functions as both IL-2 and IL-15. However, it specifically lacks the binding site of IL-2 receptor α subunit (CD25), therefore unable to induce the Treg proliferation. In present study, a recombinant vesicular stomatitis virus expressing the Neo-2/15 (VSV

Indexed as

Interleukin-2Oncolytic VirotherapyOncolytic VirusesAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunotherapyInterleukin-15MiceMice, Inbred BALB CNeoplasmsT-Lymphocytes, RegulatoryTumor MicroenvironmentVesiculovirusInterleukin-15Interleukin-2Combination therapyIL-2 mimicNeo-2/15Oncolytic virus (OV)Tumor immunityVesicular Stomatitis virus (VSV)

Identifiers

PMID39299564
PMCPMC11738782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.